Clinical trials: Histological Response
Liver Cancer, Liver Tumor
Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation
The purpose of this study is to prospectively analyze the value of 3D ultrasound perfusion imaging for treatment planning, the prediction of therapy success, and to monitor the treatment response in patients with a primary or…
- Conditions
- Liver Cancer, Liver Tumor, Hepatocellular Carcinoma, Liver Carcinoma
- Trial name
- NCT02424955
- Testing
- perflutren lipid microspheres, 3D ultrasound
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
5-Fluorouracil Response and Optimization STudy (The FROST Trial)
This randomized phase II trial will characterize the efficacy, adverse event (AE) profile, and safety of two regimens of 5-FU given as 2L+ treatment to patients with RM-HNSCC.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT07419464
- Testing
- 5-Fluorouracil
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Washington University School of Medicine
Melanoma, Advanced Melanoma
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
This is a non-therapeutic study assessing peripheral T cell determinants of response and resistance to immunotherapy in patients with advanced melanoma.The hypothesis is that systemic T cells traffic into the tumor…
- Trial name
- NCT05105100
- Testing
- Biopsy, Biospecimen Collection
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia
CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia
This is a single-center, open-label, single-arm, prospective, investigator-initiated dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an autologous CLL-1/CD70 dual-target CAR-T cell…
- Trial name
- NCT07897136
- Testing
- CLL-1-CD70 CAR-T Cell Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Liping Dou
Recurrent Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma
An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas
This study evaluates the use of a new imaging agent called fluorodopa F 18 (18F-DOPA) with positron emission tomography/magnetic resonance imaging (PET/MRI) for assessing treatment response in patients undergoing standard of care…
- Conditions
- Recurrent Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma
- Trial name
- NCT05560009
- Testing
- Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Leukemia
Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
- Trial name
- NCT01169363
- Testing
- proteomic profiling, flow cytometry, laboratory biomarker analysis
- Volunteers
- 200 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lymphoma
Vaccine Responses in Patients With B Cell Malignancies
Background: People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or certain vaccines.
- Trial name
- NCT05170399
- Testing
- AREXVY, ABRYSVO, PREVNAR 20, PNEUMOVAX 23
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Alzheimer's Disease
Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)
This study will evaluate the safety and tolerability and Aß-specific antibody response of CAD106 in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00411580
- Testing
- CAD106
- Where
- 3 sites in Sweden
- Volunteers
- 58 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, B-Cell, Marginal Zone
Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
Investigate the efficacy and safety of Orelabrutinib followed by response-adapted ultra-low dose 4Gy radiation in the treatment of local-stage MALT lymphoma
- Trial name
- NCT06583837
- Testing
- Orelabrutinib, response-adapted radiation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Melanoma Stage III or IV
Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients
Dendritic cells (DCs)are the most potent antigen-presenting cells of the immune system, as such they are able to direct the immune system specifically against cancer cells.
- Trial name
- NCT00243529
- Testing
- autologous dendritic cell vaccine
- Where
- Netherlands
- Volunteers
- 64 people
- Sponsor
- Radboud University Medical Center
Multiple Myeloma
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment.
- Trial name
- MASTER-2 (NCT05231629)
- Testing
- Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of Alabama at Birmingham
Non-Hodgkin Lymphoma, Cytokine Release Syndrome
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
The goal of this clinical trial is to is to determine the safety, feasibility and efficacy of siltuximab prophylaxis of cytokine release syndrome and neurotoxicity occurring after epcoritamab subcutaneous administration for…
- Trial name
- NCT06447376
- Testing
- Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Taylor Brooks
Recurrent Melanoma, Stage IV Melanoma
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
This phase II trial studies intermittent dosing of BRAF inhibitor LGX818 (encorafenib) and MEK inhibitor MEK 162 (binimetinib) in treating patients with melanoma that has spread to other parts of the body (metastatic) and have a…
- Trial name
- NCT02263898
- Testing
- Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioblastoma Multiforme, GBM
FET-PET for Evaluation of Response of Recurrent GBM to Avastin
Hypothesis: The central hypothesis underlying the proposed research study is that FET-PET will predict durable benefit in patients receiving anti-angiogenic benefit for presumed recurrent GBM (i.e.
- Trial name
- NCT01756352
- Testing
- 18F-FET
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Marcelo F. Di Carli, MD, FACC
Basal Cell Carcinoma
Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Photodynamic therapy (PDT) is the selective destruction of abnormal cells through light activation of a photosensitiser in the presence of oxygen. These cells accumulate more photosensitiser than normal cells.
- Trial name
- NCT00473343
- Testing
- Metvix® cream
- Where
- 7 sites in Australia
- Volunteers
- 102 people
- Sponsor
- Galderma R&D
Chronic Myelogenous Leukemia
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
The results of the International Randomized Study of Interferon and STI571 (IRIS) trial indicate that in patients with chronic phase CML treated with first line imatinib, achievement of a complete or partial cytogenetic response…
- Trial name
- NCT01316250
- Testing
- Nilotinib
- Where
- Lebanon
- Volunteers
- 13 people
- Sponsor
- American University of Beirut Medical Center
Multiple Myeloma
Inflammatory Cytokines in Symptom Production in Multiple Myeloma
The goal of this research study is to learn about the pain and/or other symptoms that patients may experience either while you are being monitored by your doctor before a decision is made to start you on treatment for your MM, or…
- Trial name
- NCT00688168
- Testing
- Questionnaire, Neurocognitive Testing, Neurosensory Testing
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of Lung Stage IV, Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in, Somatic
Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center
The recent discovery of oncogenic drivers has revolutionized the management of advanced lung cancer by development of tyrosine kinase inhibitors targeted therapies.
- Trial name
- NCT04493827
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Central Hospital, Nancy, France
Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
This 2 arm study will compare the efficacy and safety of the standard chemotherapy of the East German Study Group for Hematology and Oncology versus standard chemotherapy plus MabThera (375mg/m2 iv, once monthly for 8 cycles) in…
- Trial name
- NCT00269113
- Testing
- rituximab [MabThera/Rituxan], Standard chemotherapy
- Where
- 33 sites in Germany
- Volunteers
- 360 people
- Sponsor
- Hoffmann-La Roche
Cholangiocarcinoma
International Registry on Cholangiocarcinoma Treatment
Cholangiocarcinoma is a rare and very aggressive neoplasm that arises from the biliary epithelium, constitutes approximately 2% of all reported cancer, and accounts for about 3% of all gastrointestinal malignancies.
- Trial name
- CHOLANGIO (NCT01920503)
- Testing
- Doxorubicin
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- International Group of Endovascular Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.